Cyclin E, a potential prognostic marker for breast cancer

Area of Science:

• Molecular Biology
• Oncology
• Cell Cycle Regulation

Background:

• Cancer arises from genetic alterations that disrupt normal tissue development and promote tumor cell growth.
• Cell cycle deregulation, often due to altered protein production (e.g., tumor suppressors, oncogenes), drives uncontrolled proliferation.
• A universal genetic alteration common to all cancers has not been identified.

Purpose of the Study:

• To investigate alterations in cyclin E protein production in various human malignancies.
• To determine if cyclin E alterations are specific to tumor tissue compared to normal tissue.
• To evaluate the correlation between cyclin E expression changes and tumor stage/grade in breast cancer.

Main Methods:

• Analysis of surgical specimens from patients with diverse cancers, including breast cancer, other solid tumors, and lymphatic leukemia.
• Quantitative and qualitative assessment of cyclin E protein levels.
• Correlation analysis of cyclin E alterations with S-phase fraction, tumor stage, and tumor grade.

Main Results:

• Severe quantitative and qualitative alterations in cyclin E protein production were observed in breast cancers, other solid tumors, and malignant lymphocytes.
• These cyclin E alterations were independent of the S-phase fraction, indicating a fundamental difference between normal and tumor tissues.
• In breast cancer, cyclin E expression alterations worsened with increasing tumor stage and grade.

Conclusions:

• Altered cyclin E protein production is a significant characteristic of various cancers, distinguishing tumor tissue from normal tissue.
• Cyclin E alterations represent a fundamental aspect of cancer biology, linked to cell cycle deregulation.
• Cyclin E shows promise as a novel prognostic marker for breast cancer, correlating with disease progression.